The Amphibolous Role of miR-203 in Gastrointestinal and Urogenital Cancers
International Journal of Animal Science and Technology
Volume 1, Issue 1, December 2017, Pages: 5-14
Received: Oct. 30, 2017; Accepted: Nov. 16, 2017; Published: Jan. 3, 2018
Views 102      Downloads 10
Authors
Lei Zhan, Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
Bing Wei, Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
Article Tools
Follow on us
Abstract
miR-203, as a member of the miRNAs family, play a major role in control of gene expression during normal development and are disrupted in the initiation and progression of specific diseases. It was worth nothing that a growing body of evidence indicated an abnormal expression of miR-203 in several human leading cancers including gastrointestinal and urogenital cancers. The cytosine-phosphoguanine (CpG)-island methylation was one of the most significant factors which controlled the expression of miR-203. Furthermore, miR-203 participated in these cancers via targeting its downstream genes. However, the precise regulatory mechanisms underlying miR-203 association with these cancers are still not fully understood. The aim of this review is to sum up the collective knowledge of miR-203 in gastrointestinal and urogenital cancers.
Keywords
miR-203, Gastrointestinal Cancers, Urogenital Cancers, Methylation, Targeting
To cite this article
Lei Zhan, Bing Wei, The Amphibolous Role of miR-203 in Gastrointestinal and Urogenital Cancers, International Journal of Animal Science and Technology. Vol. 1, No. 1, 2017, pp. 5-14. doi: 10.11648/j.ijast.20170101.12
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
J. A. Vidigal, A. Ventura, The biological functions of miRNAs: lessons from in vivo studies, Trends Cell Biol 25 (3) (2015) 137-47.
[2]
N. C. Lau, L. P. Lim, E. G. Weinstein, D. P. Bartel, An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans, Science 294 (5543) (2001) 858-62.
[3]
W. Filipowicz, S. N. Bhattacharyya, N. Sonenberg, Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?, Nature reviews. Genetics 9 (2) (2008) 102-14.
[4]
Z. H. Wu, L. M. Pfeffer, MicroRNA regulation of F-box proteins and its role in cancer, Semin Cancer Biol (2015).
[5]
B. P. Towler, C. I. Jones, S. F. Newbury, Mechanisms of regulation of mature miRNAs, Biochem Soc Trans 43 (6) (2015) 1208-14.
[6]
A. Kozomara, S. Griffiths-Jones, miRBase: integrating microRNA annotation and deep-sequencing data, Nucleic acids research 39 (Database issue) (2011) D152-7.
[7]
J. Masliah-Planchon, S. Garinet, E. Pasmant, RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action, Oncotarget (2015).
[8]
Y. He, J. Lin, D. Kong, M. Huang, C. Xu, T. K. Kim, A. Etheridge, Y. Luo, Y. Ding, K. Wang, Current State of Circulating MicroRNAs as Cancer Biomarkers, Clin Chem 61 (9) (2015) 1138-55.
[9]
G. Bertoli, C. Cava, I. Castiglioni, MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer, Theranostics 5 (10) (2015) 1122-43.
[10]
E. S. Lianidou, Gene expression profiling and DNA methylation analyses of CTCs, Mol Oncol 10 (3) (2016) 431-42.
[11]
S. Noguchi, T. Mori, T. Nakagawa, K. Itamoto, T. Haraguchi, T. Mizuno, DNA methylation contributes toward silencing of antioncogenic microRNA-203 in human and canine melanoma cells, Melanoma Res 25 (5) (2015) 390-8.
[12]
R. Yi, M. N. Poy, M. Stoffel, E. Fuchs, A skin microRNA promotes differentiation by repressing 'stemness', Nature 452 (7184) (2008) 225-9.
[13]
W. Wei, L. Wanjun, S. Hui, C. Dongyue, Y. Xinjun, Z. Jisheng, miR-203 inhibits proliferation of HCC cells by targeting survivin, Cell biochemistry and function 31 (1) (2013) 82-5.
[14]
Z. Zhang, B. Zhang, W. Li, L. Fu, Z. Zhu, J. T. Dong, Epigenetic Silencing of miR-203 Upregulates SNAI2 and Contributes to the Invasiveness of Malignant Breast Cancer Cells, Genes Cancer 2 (8) (2011) 782-91.
[15]
M. V. Iorio, R. Visone, G. Di Leva, V. Donati, F. Petrocca, P. Casalini, C. Taccioli, S. Volinia, C. G. Liu, H. Alder, G. A. Calin, S. Menard, C. M. Croce, MicroRNA signatures in human ovarian cancer, Cancer Res 67 (18) (2007) 8699-707.
[16]
D. D. Taylor, C. Gercel-Taylor, MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer, Gynecol Oncol 110 (1) (2008) 13-21.
[17]
A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, D. Forman, Global cancer statistics, CA: a cancer journal for clinicians 61 (2) (2011) 69-90.
[18]
Y. Ladeiro, G. Couchy, C. Balabaud, P. Bioulac-Sage, L. Pelletier, S. Rebouissou, J. Zucman-Rossi, MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations, Hepatology 47 (6) (2008) 1955-63.
[19]
M. Furuta, K. I. Kozaki, S. Tanaka, S. Arii, I. Imoto, J. Inazawa, miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma, Carcinogenesis 31 (5) (2010) 766-76.
[20]
H. Y. Chen, Z. B. Han, J. W. Fan, J. Xia, J. Y. Wu, G. Q. Qiu, H. M. Tang, Z. H. Peng, miR-203 expression predicts outcome after liver transplantation for hepatocellular carcinoma in cirrhotic liver, Medical oncology 29 (3) (2012) 1859-65.
[21]
Y. Liu, F. Ren, M. Rong, Y. Luo, Y. Dang, G. Chen, Association between underexpression of microrna-203 and clinicopathological significance in hepatocellular carcinoma tissues, Cancer Cell Int 15 (2015) 62.
[22]
D. Wan, S. Shen, S. Fu, C. Shen, J. Wu, S. Wang, W. Xie, B. Chen, L. A, Y. Guo, D. Zheng, Q. Zhi, B. Peng, miR-203 suppresses the proliferation and metastasis of hepatocellular carcinoma by targeting oncogene ADAM9 and oncogenic long non-coding RNA HULC, Anticancer Agents Med Chem (2015).
[23]
F. Yang, L. Z. Lv, Q. C. Cai, Y. Jiang, Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma cell line Hep3B, World J Gastroenterol 21 (47) (2015) 13268-76.
[24]
D. Liu, J. Wu, M. Liu, H. Yin, J. He, B. Zhang, Downregulation of miRNA-30c and miR-203a is associated with hepatitis C virus core protein-induced epithelial-mesenchymal transition in normal hepatocytes and hepatocellular carcinoma cells, Biochem Biophys Res Commun 464 (4) (2015) 1215-21.
[25]
P. Bertuccio, L. Chatenoud, F. Levi, D. Praud, J. Ferlay, E. Negri, M. Malvezzi, C. La Vecchia, Recent patterns in gastric cancer: a global overview, International journal of cancer. Journal international du cancer 125 (3) (2009) 666-73.
[26]
Y. Chiang, Y. Song, Z. Wang, Y. Chen, Z. Yue, H. Xu, C. Xing, Z. Liu, Aberrant expression of miR-203 and its clinical significance in gastric and colorectal cancers, Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract 15 (1) (2011) 63-70.
[27]
H. H. Zhang, G. L. Gu, X. Y. Zhang, F. Z. Li, L. Ding, Q. Fan, R. Wu, W. Shi, X. Y. Wang, L. Chen, X. M. Wei, X. Y. Yuan, Primary analysis and screening of microRNAs in gastric cancer side population cells, World journal of gastroenterology: WJG 21 (12) (2015) 3519-26.
[28]
V. J. Craig, S. B. Cogliatti, H. Rehrauer, T. Wundisch, A. Muller, Epigenetic silencing of microRNA-203 dysregulates ABL1 expression and drives Helicobacter-associated gastric lymphomagenesis, Cancer research 71 (10) (2011) 3616-24.
[29]
Y. Du, Z. Liu, L. Gu, J. Zhou, B. D. Zhu, J. Ji, D. Deng, Characterization of human gastric carcinoma-related methylation of 9 miR CpG islands and repression of their expressions in vitro and in vivo, BMC Cancer 12 (2012) 249.
[30]
X. Zhou, G. Xu, C. Yin, W. Jin, G. Zhang, Down-regulation of miR-203 induced by Helicobacter pylori infection promotes the proliferation and invasion of gastric cancer by targeting CASK, Oncotarget 5 (22) (2014) 11631-40.
[31]
Y. Shi, Y. J. Tan, D. Z. Zeng, F. Qian, P. W. Yu, miR-203 suppression in gastric carcinoma promotes Slug-mediated cancer metastasis, Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine (2015).
[32]
H. Imaoka, Y. Toiyama, M. Okigami, H. Yasuda, S. Saigusa, M. Ohi, K. Tanaka, Y. Inoue, Y. Mohri, M. Kusunoki, Circulating microRNA-203 predicts metastases, early recurrence, and poor prognosis in human gastric cancer, Gastric Cancer (2015).
[33]
E. Stanitz, K. Juhasz, C. Toth, K. Gombos, P. G. Natali, I. Ember, Evaluation of MicroRNA expression pattern of gastric adenocarcinoma associated with socioeconomic, environmental and lifestyle factors in northwestern Hungary, Anticancer research 33 (8) (2013) 3195-200.
[34]
J. L. Cameron, T. S. Riall, J. Coleman, K. A. Belcher, One thousand consecutive pancreaticoduodenectomies, Ann Surg 244 (1) (2006) 10-5.
[35]
T. Greither, L. F. Grochola, A. Udelnow, C. Lautenschlager, P. Wurl, H. Taubert, Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival, International journal of cancer. Journal international du cancer 126 (1) (2010) 73-80.
[36]
S. Yabushita, K. Fukamachi, H. Tanaka, K. Sumida, Y. Deguchi, T. Sukata, S. Kawamura, S. Uwagawa, M. Suzui, H. Tsuda, Circulating microRNAs in serum of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas, Pancreas 41 (7) (2012) 1013-8.
[37]
N. Ikenaga, K. Ohuchida, K. Mizumoto, J. Yu, T. Kayashima, H. Sakai, H. Fujita, K. Nakata, M. Tanaka, MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma, Annals of surgical oncology 17 (12) (2010) 3120-8.
[38]
S. Ali, H. Dubaybo, R. E. Brand, F. H. Sarkar, Differential Expression of MicroRNAs in Tissues and Plasma Co-exists as a Biomarker for Pancreatic Cancer, J Cancer Sci Ther 7 (11) (2015) 336-346.
[39]
J. Yu, A. Li, S. M. Hong, R. H. Hruban, M. Goggins, MicroRNA alterations of pancreatic intraepithelial neoplasias, Clinical cancer research: an official journal of the American Association for Cancer Research 18 (4) (2012) 981-92.
[40]
Z. G. Ren, S. X. Dong, P. Han, J. Qi, miR-203 promotes proliferation, migration and invasion by degrading SIK1 in pancreatic cancer, Oncol Rep 35 (3) (2016) 1365-74.
[41]
L. Miao, X. Xiong, Y. Lin, Y. Cheng, J. Lu, J. Zhang, N. Cheng, miR-203 inhibits tumor cell migration and invasion via caveolin-1 in pancreatic cancer cells, Oncol Lett 7 (3) (2014) 658-662.
[42]
M. Zhou, J. Chen, L. Zhou, W. Chen, G. Ding, L. Cao, Pancreatic cancer derived exosomes regulate the expression of TLR4 in dendritic cells via miR-203, Cellular immunology 292 (1-2) (2014) 65-9.
[43]
S. Meidhof, S. Brabletz, W. Lehmann, B. T. Preca, K. Mock, M. Ruh, J. Schuler, M. Berthold, A. Weber, U. Burk, M. Lubbert, M. Puhr, Z. Culig, U. Wellner, T. Keck, P. Bronsert, S. Kusters, U. T. Hopt, M. P. Stemmler, T. Brabletz, ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat, EMBO Mol Med 7 (6) (2015) 831-47.
[44]
A. E. Frampton, J. Krell, N. B. Jamieson, T. M. Gall, E. Giovannetti, N. Funel, M. Mato Prado, D. Krell, N. A. Habib, L. Castellano, L. R. Jiao, J. Stebbing, microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis, European journal of cancer 51 (11) (2015) 1389-404.
[45]
P. C. Enzinger, R. J. Mayer, Esophageal cancer, The New England journal of medicine 349 (23) (2003) 2241-52.
[46]
A. Feber, L. Xi, J. D. Luketich, A. Pennathur, R. J. Landreneau, M. Wu, S. J. Swanson, T. E. Godfrey, V. R. Litle, MicroRNA expression profiles of esophageal cancer, The Journal of thoracic and cardiovascular surgery 135 (2) (2008) 255-60; discussion 260.
[47]
L. Zhu, W. Yan, J. Rodriguez-Canales, A. M. Rosenberg, N. Hu, A. M. Goldstein, P. R. Taylor, H. S. Erickson, M. R. Emmert-Buck, M. A. Tangrea, MicroRNA analysis of microdissected normal squamous esophageal epithelium and tumor cells, American journal of cancer research 1 (5) (2011) 574-584.
[48]
R. Saad, Z. Chen, S. Zhu, P. Jia, Z. Zhao, M. K. Washington, A. Belkhiri, W. El-Rifai, Deciphering the unique microRNA signature in human esophageal adenocarcinoma, PloS one 8 (5) (2013) e64463.
[49]
H. B. Wang, Z. B. Jiang, M. Li, Research on the Typical miRNA and Target Genes in Squamous Cell Carcinoma and Adenocarcinoma of Esophagus Cancer with DNA Microarray, Pathology oncology research: POR (2014).
[50]
Y. Yuan, Z. Y. Zeng, X. H. Liu, D. J. Gong, J. Tao, H. Z. Cheng, S. D. Huang, MicroRNA-203 inhibits cell proliferation by repressing DeltaNp63 expression in human esophageal squamous cell carcinoma, BMC cancer 11 (2011) 57.
[51]
M. Cao, X. Deng, S. Su, F. Zhang, X. Xiao, Q. Hu, Y. Fu, B. B. Yang, Y. Wu, W. Sheng, Y. Zeng, Protamine sulfate-nanodiamond hybrid nanoparticles as a vector for MiR-203 restoration in esophageal carcinoma cells, Nanoscale 5 (24) (2013) 12120-5.
[52]
F. Zhang, Z. Yang, M. Cao, Y. Xu, J. Li, X. Chen, Z. Gao, J. Xin, S. Zhou, Z. Zhou, Y. Yang, W. Sheng, Y. Zeng, MiR-203 suppresses tumor growth and invasion and down-regulates MiR-21 expression through repressing Ran in esophageal cancer, Cancer letters 342 (1) (2014) 121-9.
[53]
N. Takeshita, M. Mori, M. Kano, I. Hoshino, Y. Akutsu, N. Hanari, Y. Yoneyama, N. Ikeda, Y. Isozaki, T. Maruyama, N. Akanuma, Y. Miyazawa, H. Matsubara, miR-203 inhibits the migration and invasion of esophageal squamous cell carcinoma by regulating LASP1, International journal of oncology 41 (5) (2012) 1653-61.
[54]
X. Yu, X. Jiang, H. Li, L. Guo, W. Jiang, S. H. Lu, miR-203 inhibits the proliferation and self-renewal of esophageal cancer stem-like cells by suppressing stem renewal factor Bmi-1, Stem Cells Dev 23 (6) (2014) 576-85.
[55]
T. Okumura, Y. Shimada, M. Moriyama, Y. Takei, T. Omura, S. Sekine, T. Nagata, K. Shimizu, K. Tsukada, MicroRNA-203 inhibits the progression of esophageal squamous cell carcinoma with restored epithelial tissue architecture in vivo, International journal of oncology 44 (6) (2014) 1923-32.
[56]
K. Zhang, L. Dai, B. Zhang, X. Xu, J. Shi, L. Fu, X. Chen, J. Li, Y. Bai, miR-203 is a direct transcriptional target of E2F1 and causes G1 arrest in esophageal cancer cells, Journal of cellular physiology 230 (4) (2015) 903-10.
[57]
J. Li, F. Shan, G. Xiong, X. Chen, X. Guan, J. M. Wang, W. L. Wang, X. Xu, Y. Bai, EGF-induced C/EBPbeta participates in EMT by decreasing the expression of miR-203 in esophageal squamous cell carcinoma cells, Journal of cell science 127 (Pt 17) (2014) 3735-44.
[58]
J. Coget, F. Borrini, S. Susman, J. C. Sabourin, Colorectal carcinomas in 2013: the search for powerful prognostic markers is still on the go!, Cancer Biomark 14 (2-3) (2014) 145-50.
[59]
A. G. Xu, Z. J. Yu, B. Jiang, X. Y. Wang, X. H. Zhong, J. H. Liu, Q. Y. Lou, A. H. Gan, Colorectal cancer in Guangdong Province of China: a demographic and anatomic survey, World J Gastroenterol 16 (8) (2010) 960-5.
[60]
L. Kelland, The resurgence of platinum-based cancer chemotherapy, Nat Rev Cancer 7 (8) (2007) 573-84.
[61]
S. Y. Ju, S. H. Chiou, Y. Su, Maintenance of the stemness in CD44 (+) HCT-15 and HCT-116 human colon cancer cells requires miR-203 suppression, Stem Cell Res 12 (1) (2014) 86-100.
[62]
J. Li, Y. Chen, J. Zhao, F. Kong, Y. Zhang, miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression, Cancer Lett 304 (1) (2011) 52-9.
[63]
T. Li, F. Gao, X. P. Zhang, miR-203 enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer, Oncol Rep 33 (2) (2015) 607-14.
[64]
Y. Zhou, G. Wan, R. Spizzo, C. Ivan, R. Mathur, X. Hu, X. Ye, J. Lu, F. Fan, L. Xia, G. A. Calin, L. M. Ellis, X. Lu, miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase, Mol Oncol 8 (1) (2014) 83-92.
[65]
V. Abella, M. Valladares, T. Rodriguez, M. Haz, M. Blanco, N. Tarrio, P. Iglesias, L. A. Aparicio, A. Figueroa, miR-203 regulates cell proliferation through its influence on Hakai expression, PLoS One 7 (12) (2012) e52568.
[66]
Z. Li, L. Du, Z. Dong, Y. Yang, X. Zhang, L. Wang, J. Li, G. Zheng, A. Qu, C. Wang, MiR-203 suppresses ZNF217 upregulation in colorectal cancer and its oncogenicity, PLoS One 10 (1) (2015) e0116170.
[67]
R. L. Siegel, K. D. Miller, A. Jemal, Cancer statistics, 2015, CA: a cancer journal for clinicians 65 (1) (2015) 5-29.
[68]
S. Saini, S. Majid, S. Yamamura, L. Tabatabai, S. O. Suh, V. Shahryari, Y. Chen, G. Deng, Y. Tanaka, R. Dahiya, Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis, Clinical cancer research: an official journal of the American Association for Cancer Research 17 (16) (2011) 5287-98.
[69]
J. Xiang, C. Bian, H. Wang, S. Huang, D. Wu, MiR-203 down-regulates Rap1A and suppresses cell proliferation, adhesion and invasion in prostate cancer, J Exp Clin Cancer Res 34 (2015) 8.
[70]
A. Hailer, T. G. Grunewald, M. Orth, C. Reiss, B. Kneitz, M. Spahn, E. Butt, Loss of tumor suppressor mir-203 mediates overexpression of LIM and SH3 Protein 1 (LASP1) in high-risk prostate cancer thereby increasing cell proliferation and migration, Oncotarget 5 (12) (2014) 4144-4153.
[71]
M. K. Siu, W. Abou-Kheir, J. J. Yin, Y. S. Chang, B. Barrett, F. Suau, O. Casey, W. Y. Chen, L. Fang, P. Hynes, Y. Y. Hsieh, Y. N. Liu, J. Huang, K. Kelly, Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance, Oncotarget 5 (11) (2014) 3770-84.
[72]
K. Boll, K. Reiche, K. Kasack, N. Morbt, A. K. Kretzschmar, J. M. Tomm, G. Verhaegh, J. Schalken, M. von Bergen, F. Horn, J. Hackermuller, MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma, Oncogene 32 (3) (2013) 277-85.
[73]
Y. Qu, W. C. Li, M. R. Hellem, K. Rostad, M. Popa, E. McCormack, A. M. Oyan, K. H. Kalland, X. S. Ke, MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-sufficiency of growth signals via repressing SNAI2 in prostate cells, International journal of cancer. Journal international du cancer 133 (3) (2013) 544-55.
[74]
Z. Huang, L. Zhang, X. Yi, X. Yu, Diagnostic and prognostic values of tissue hsa-miR-30c and hsa-miR-203 in prostate carcinoma, Tumour Biol (2015).
[75]
E. Guzel, O. F. Karatas, A. Semercioz, S. Ekici, S. Aykan, S. Yentur, C. J. Creighton, M. Ittmann, M. Ozen, Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer, International journal of cancer. Journal international du cancer 136 (4) (2015) 875-9.
[76]
D. D'Alo, F. Stracci, T. Cassetti, M. Scheibel, C. Pascucci, F. La Rosa, Recent trends in incidence, mortality and survival after cancer of the female breast and reproductive organs. Umbria, Italy: 1978-2005, Eur J Gynaecol Oncol 31 (2) (2010) 174-80.
[77]
J. Bo, G. Yang, K. Huo, H. Jiang, L. Zhang, D. Liu, Y. Huang, microRNA-203 suppresses bladder cancer development by repressing bcl-w expression, The FEBS journal 278 (5) (2011) 786-92.
[78]
M. Garofalo, C. Quintavalle, C. Zanca, A. De Rienzo, G. Romano, M. Acunzo, L. Puca, M. Incoronato, C. M. Croce, G. Condorelli, Akt regulates drug-induced cell death through Bcl-w downregulation, PloS one 3 (12) (2008) e4070.
[79]
S. Saini, S. Arora, S. Majid, V. Shahryari, Y. Chen, G. Deng, S. Yamamura, K. Ueno, R. Dahiya, Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer, Cancer prevention research 4 (10) (2011) 1698-709.
[80]
X. Zhang, Y. Zhang, X. Liu, A. Fang, P. Li, Z. Li, T. Liu, Y. Yang, L. Du, C. Wang, MicroRNA-203 Is a Prognostic Indicator in Bladder Cancer and Enhances Chemosensitivity to Cisplatin via Apoptosis by Targeting Bcl-w and Survivin, PloS one 10 (11) (2015) e0143441.
[81]
L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, A. Jemal, Global cancer statistics, 2012, CA: a cancer journal for clinicians 65 (2) (2015) 87-108.
[82]
K. Fite, J. Gomez-Cambronero, Downregulation of miRs 203, 887, 3619 and 182 prevent vimentin-triggered, phospholipase D (PLD)-mediated cancer cell invasion, The Journal of biological chemistry (2015).
[83]
D. Luo, J. M. Wilson, N. Harvel, J. Liu, L. Pei, S. Huang, L. Hawthorn, H. Shi, A systematic evaluation of miRNA: mRNA interactions involved in the migration and invasion of breast cancer cells, J Transl Med 11 (2013) 57.
[84]
P. Ru, R. Steele, E. C. Hsueh, R. B. Ray, Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity, Genes & cancer 2 (7) (2011) 720-7.
[85]
P. Li, Y. Guo, G. Bledsoe, Z. Yang, L. Chao, J. Chao, Kallistatin induces breast cancer cell apoptosis and autophagy by modulating Wnt signaling and microRNA synthesis, Exp Cell Res 340 (2) (2016) 305-14.
[86]
K. Fite, L. Elkhadragy, J. Gomez-Cambronero, A REPERTOIRE OF MICRO-RNAs REGULATES CANCER CELL STARVATION BY TARGETING PHOSPHOLIPASE D (PLD) IN A FEEDBACK LOOP THAT OPERATES MAXIMALLY IN CANCER CELLS, Mol Cell Biol (2016).
[87]
C. Wang, X. Zheng, C. Shen, Y. Shi, MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells, Journal of experimental & clinical cancer research: CR 31 (2012) 58.
[88]
J. Yin, G. Zheng, X. Jia, Z. Zhang, W. Zhang, Y. Song, Y. Xiong, Z. He, A Bmi1-miRNAs cross-talk modulates chemotherapy response to 5-fluorouracil in breast cancer cells, PloS one 8 (9) (2013) e73268.
[89]
H. Taipaleenmaki, G. Browne, J. Akech, J. Zustin, A. J. van Wijnen, J. L. Stein, E. Hesse, G. S. Stein, J. B. Lian, Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease, Cancer research 75 (7) (2015) 1433-44.
[90]
Y. Zhou, H. Y. Hu, W. Meng, L. Jiang, X. Zhang, J. J. Sha, Z. Lu, Y. Yao, MEK inhibitor effective against proliferation in breast cancer cell, Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 35 (9) (2014) 9269-79.
[91]
R. Sandhu, A. G. Rivenbark, W. B. Coleman, Loss of post-transcriptional regulation of DNMT3b by microRNAs: a possible molecular mechanism for the hypermethylation defect observed in a subset of breast cancer cell lines, International journal of oncology 41 (2) (2012) 721-32.
[92]
R. Sandhu, A. G. Rivenbark, R. M. Mackler, C. A. Livasy, W. B. Coleman, Dysregulation of microRNA expression drives aberrant DNA hypermethylation in basal-like breast cancer, International journal of oncology 44 (2) (2014) 563-72.
[93]
Z. Zhang, B. Zhang, W. Li, L. Fu, L. Fu, Z. Zhu, J. T. Dong, Epigenetic Silencing of miR-203 Upregulates SNAI2 and Contributes to the Invasiveness of Malignant Breast Cancer Cells, Genes & cancer 2 (8) (2011) 782-91.
[94]
D. Madhavan, C. Peng, M. Wallwiener, M. Zucknick, J. Nees, S. Schott, A. Rudolph, S. Riethdorf, A. Trumpp, K. Pantel, C. Sohn, J. Chang-Claude, A. Schneeweiss, B. Burwinkel, Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis, Carcinogenesis (2016).
[95]
W. Song, H. G. Jeon, Incidence of kidney, bladder, and prostate cancers in Korea: An update, Korean J Urol 56 (6) (2015) 422-8.
[96]
D. Petillo, E. J. Kort, J. Anema, K. A. Furge, X. J. Yang, B. T. Teh, MicroRNA profiling of human kidney cancer subtypes, International journal of oncology 35 (1) (2009) 109-14.
[97]
S. Zhao, D. S. Yao, J. Y. Chen, N. Ding, Aberrant expression of miR-20a and miR-203 in cervical cancer, Asian Pacific journal of cancer prevention: APJCP 14 (4) (2013) 2289-93.
[98]
M. Seifoleslami, M. K. Khameneie, F. Mashayekhi, F. Sedaghati, K. Ziari, K. Mansouri, A. Safari, Identification of microRNAs (miR-203/miR-7) as potential markers for the early detection of lymph node metastases in patients with cervical cancer, Tumour Biol (2015).
[99]
L. Mao, Y. Zhang, W. Mo, Y. Yu, H. Lu, BANF1 is downregulated by IRF1-regulated microRNA-203 in cervical cancer, PloS one 10 (2) (2015) e0117035.
[100]
X. Zhu, K. Er, C. Mao, Q. Yan, H. Xu, Y. Zhang, J. Zhu, F. Cui, W. Zhao, H. Shi, miR-203 suppresses tumor growth and angiogenesis by targeting VEGFA in cervical cancer, Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology 32 (1) (2013) 64-73.
[101]
S. Zhao, D. Yao, J. Chen, N. Ding, Circulating miRNA-20a and miRNA-203 for screening lymph node metastasis in early stage cervical cancer, Genetic testing and molecular biomarkers 17 (8) (2013) 631-6.
[102]
K. Gocze, K. Gombos, K. Juhasz, K. Kovacs, B. Kajtar, M. Benczik, P. Gocze, B. Patczai, I. Arany, I. Ember, Unique microRNA expression profiles in cervical cancer, Anticancer research 33 (6) (2013) 2561-7.
[103]
A. Botezatu, C. D. Goia-Rusanu, I. V. Iancu, I. Huica, A. Plesa, D. Socolov, C. Ungureanu, G. Anton, Quantitative analysis of the relationship between microRNA124a, -34b and -203 gene methylation and cervical oncogenesis, Molecular medicine reports 4 (1) (2011) 121-8.
[104]
Y. W. Huang, C. T. Kuo, J. H. Chen, P. J. Goodfellow, T. H. Huang, J. S. Rader, D. S. Uyar, Hypermethylation of miR-203 in endometrial carcinomas, Gynecol Oncol 133 (2) (2014) 340-5.
[105]
S. Wang, X. Zhao, J. Wang, Y. Wen, L. Zhang, D. Wang, H. Chen, Q. Chen, W. Xiang, Upregulation of microRNA-203 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer, Medical oncology 30 (3) (2013) 681.
[106]
G. Zhao, Y. Guo, Z. Chen, Y. Wang, C. Yang, A. Dudas, Z. Du, W. Liu, Y. Zou, E. Szabo, S. C. Lee, M. Sims, W. Gu, T. Tillmanns, L. M. Pfeffer, G. Tigyi, J. Yue, miR-203 Functions as a Tumor Suppressor by Inhibiting Epithelial to Mesenchymal Transition in Ovarian Cancer, J Cancer Sci Ther 7 (2) (2015) 34-43.
[107]
T. K. Chung, T. H. Cheung, N. Y. Huen, K. W. Wong, K. W. Lo, S. F. Yim, N. S. Siu, Y. M. Wong, P. T. Tsang, M. W. Pang, M. Y. Yu, K. F. To, S. C. Mok, V. W. Wang, C. Li, A. Y. Cheung, G. Doran, M. J. Birrer, D. I. Smith, Y. F. Wong, Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women, Int J Cancer 124 (6) (2009) 1358-65.
[108]
M. A. Castilla, G. Moreno-Bueno, L. Romero-Perez, K. Van De Vijver, M. Biscuola, M. A. Lopez-Garcia, J. Prat, X. Matias-Guiu, A. Cano, E. Oliva, J. Palacios, Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma, J Pathol 223 (1) (2011) 72-80.
ADDRESS
Science Publishing Group
548 FASHION AVENUE
NEW YORK, NY 10018
U.S.A.
Tel: (001)347-688-8931